Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
First Launch For Dayvigo In Asia Outside Of Japan
TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan.
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm.
Alzheimer’s Disease Treatment Market Value Predicted To Reach US$ 5,647.5 Million By 2027: Acumen Research And Consulting Acumen Research and Consulting Pune, INDIA
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled
“Alzheimer’s Disease Treatment Market– Global Industry Analysis, Market Size, Opportunities and Forecast, 2020-2027”
LOS ANGELES, April 07, 2021 (GLOBE NEWSWIRE) The
Global Alzheimer’s Disease Treatment Market is expected to grow at a CAGR of around 12.8% from 2020 to 2027 and reach the market value of over US$ 5,647.5 Mn by 2027.
North America takes a strong lead in the Alzheimer’s disease treatment market. Factors responsible for the growth of regional market involves high prevalence of the disease, with rising cases resulting in spreading awareness of early diagnosis of the disease, accelerated demand for advanced therapies and diagnostic tool with mod
Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
The Business Research Company’s Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON, UK, April 1, 2021 /EINPresswire.com/ Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports
Increasing R&D investments and collaborations due to the emerging technologies for treatment is a key trend in Alzheimer’s disease (AD) treatment market. The Alzheimer s Association is assisting with funds for researchers in search of innovative therapeutic approaches, and seeks more government funding for Alzheimer s studies. Technologies such as ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborate
New Drug Approval for in-House Developed Anti-Insomnia Drug Dayvigo (Lemborexant) in Hong Kong
First Drug Approval for Dayvigo in Asia Outside of Japan
TOKYO, Mar 2, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has obtained approval for the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. This approval is the first approval for DAYVIGO in Asia outside of Japan.
DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R). DAYVIGO acts on the orexin neurotransmitter system and is believed to facilitate sleep onset, sleep maintenance, and wake by regulating sleep-wake rhythm. DAYVIGO binds to orexin receptors OX1R and OX2R and ac
Share this article
Share this article
ResearchAndMarkets.com s offering.
Major players in the Alzheimer s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.
The global Alzheimer s disease treatment market is expected to decline from $3.46 billion in 2019 to $3.42 billion in 2020 at a compound annual growth rate (CAGR) of -1.26%.
The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $4.96 billion in 2023 at a CAGR of 13.21%.